HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

引言CAR-T（嵌合抗原受体T细胞）疗法在血液系统恶性肿瘤的治疗中取得了突破性进展。然而，由于实体瘤的肿瘤微环境（TME）高度免疫抑制、肿瘤抗原表达的异质性及T细胞渗透能力受限，CAR-T在实体瘤治疗中面临显著挑战。为克服这些问题，2月7日Natur ...

Eating well can help support your immune system and maintain strength and energy if you have HER2-negative breast cancer, ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now approved for use in Thailand.[1,2,3] ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...